Aetna specialty drug prior authorization — care coordinator playbook

End-to-end PA workflow

Aetna specialty drug prior authorization is a four-phase workflow for the PCC: benefits investigation through Availity Essentials or the aetna.com eligibility tool, hub program enrollment for benefits investigation support and copay or bridge-supply assistance, PA submission through the correct portal (medical-benefit via Availity / aetna.com, pharmacy-benefit via CVS Caremark, white-bag via CVS Specialty referral or Naviport), and reauth tracking. Where billers most often trip on Aetna is the Availity vs aetna.com vs CVS Caremark portal choice, the Cordavis adalimumab biosimilar mandate (where Humira is denied without documented step-through), and the SilverScript-vs-Aetna-MA Part D / Part B confusion on dual-benefit members.

Where the Aetna workflow breaks

Four failure patterns drive the bulk of stalled Aetna specialty PAs:

1. Wrong portal. A medical-benefit drug submitted to CVS Caremark (or a pharmacy-benefit drug submitted via Availity to Aetna's medical PA queue) gets bounced silently or routed into a queue with a different criteria set. The Availity vs aetna.com choice is mostly operational, but the medical vs pharmacy vs CVS Specialty distinction is hard-routed.
2. Missing Cordavis biosimilar step-through. Aetna's 2024-2026 adalimumab biosimilar policy requires documented intolerance, immunogenicity, or failure on a Cordavis-distributed adalimumab biosimilar before approving reference Humira. The same logic applies to bevacizumab, infliximab, rituximab, trastuzumab, and pegfilgrastim biosimilar mandates.
3. CVS Specialty out-of-network. When a patient is dispensed a specialty drug through a non-CVS Specialty pharmacy on a plan where CVS Specialty is the mandated in-network specialty pharmacy, the resulting claim is denied for OON SP — even if the underlying drug PA was approved.
4. SilverScript vs Aetna MA confusion. A Part B physician-administered drug request submitted to SilverScript (Part D PDP) goes nowhere, and a Part D self-administered drug request submitted to Aetna MA's medical PA queue gets bounced. Always verify the member's plan ID and benefit channel before submitting.

Provider portals

Aetna's specialty drug ecosystem spans at least five distinct provider-facing portals, and the choice of portal is determined by the benefit channel, the dispensing model, and whether the practice prefers a multi-payer interface (Availity) or Aetna's first-party portal.

PA fax numbers by drug class

The most reliable workflow is to download the drug-specific PA form fresh from aetna.com or caremark.com each time, since the form itself prints the current submission fax at the top. Aetna and CVS Caremark also revise fax numbers without front-page announcements — the only canonical source is the current PA form.

Peer-to-peer (P2P) review requests

Peer-to-peer review is Aetna’s pre-appeal pathway for the prescribing physician to discuss a denied or pended PA with the reviewing medical director. P2P is usually faster than a written Level 1 appeal and can resolve denials based on missing or misinterpreted clinical context. Aetna commercial, Aetna MA, and SilverScript each route to separate P2P queues with distinct phone numbers and review windows.

P2P request workflow

1. Read the denial letter. The denial letter lists the P2P scheduling phone number, the cited Aetna Clinical Policy Bulletin (CPB) reference, and the window in which a P2P can be requested (commonly 5-10 business days from the denial date for pre-service denials). Verify the line of business — commercial, Aetna MA, SilverScript, and Aetna Better Health (Medicaid managed care) each use different P2P queues.
2. Call the P2P scheduling line. Have the member ID, denial reference number, prescribing physician name and direct callback number, the cited CPB reference, and physician’s available windows over the next 3 business days. Aetna will schedule a 15-minute call window (often 24-72 hours out).
3. Confirm in writing. Document the scheduled time, the queue (commercial / MA / SilverScript / Better Health), the reviewer specialty if disclosed, and the reference number.
4. Prep the prescriber. Hand off the documentation packet (below) at least 4 hours before the call so the prescriber walks in cold-prepared, not improvising. Read the cited CPB criteria in advance so the conversation can target the specific criterion the denial cited.
5. Document the call. Capture who from Aetna participated (name and credential), the decision (approve, uphold, downgrade), reference number, and any commitments around resubmission with additional information.

Pre-call documentation checklist

• The original PA submission package (CoverMyMeds export, Availity export, or PDF).
• The denial letter with the stated denial reason and the cited Aetna Clinical Policy Bulletin reference.
• The most recent clinical note (within the last 30-60 days) supporting the indication.
• Prior therapy list with dates, doses, duration, and documented response or intolerance — including any Cordavis-distributed biosimilar trial when the denial cited biosimilar step-through.
• Compendia citation supporting any off-label use (NCCN Category 1 or 2A, DrugDex Cat I or IIa, AHFS).
• Laboratory or imaging evidence supporting the indication (e.g., HER2 IHC/FISH for HER2-targeted therapy, EGFR mutation for EGFR-targeted therapy, MRI for MS DMT).
• If site-of-care is the issue: the Aetna site-of-care exception language and the clinical rationale for HOPD administration.

Suggested prescriber talking points

Site-of-care policy

Aetna’s site-of-care steerage program is moderate — meaningful but less aggressive than UnitedHealthcare’s SUPREME-gated Outpatient Hospital Site of Care Review program. Aetna’s medical-necessity reviews for HOPD administration of high-cost specialty biologics increasingly require documented clinical reason for the HOPD setting, but the program does not blanket-deny HOPD administration in the same automated way UHC’s process does. Expect site-of-care exception language and documented HOPD necessity to be required for high-spend infusions; expect more flexibility for first-cycle administrations and complex pediatric or geriatric cases than UHC currently extends.

Site-of-care exception workflow

When HOPD administration is medically necessary, the exception pathway uses the Aetna site-of-care exception language documented in the relevant Clinical Policy Bulletin. The submission documents: the clinical reason HOPD is necessary (prior Grade 3+ infusion reaction with intervention, hemodynamic instability, concurrent comorbidity requiring HOPD-level monitoring, complex pediatric or geriatric situation), the failed or contraindicated alternative sites, the prescribing physician’s attestation, and the planned administration protocol. Submit through Availity Essentials or aetna.com PA tool with the drug PA. Site-of-care exceptions are typically decided within the same TAT as the drug PA.

Biosimilar mandate policy

Aetna has an aggressive biosimilar substitution policy across the major reference biologics, operationally enforced through the CVS Caremark formulary and the Cordavis private-label distribution arrangement. The policy applies to new starts almost universally and to continuing patients on reference product without documented clinical reason to stay on reference. Aetna’s adalimumab biosimilar mandate is the most visible 2024-2026 expansion and is structurally tied to Cordavis distribution.

Pediatric considerations

Pediatric biosimilar substitution carries additional documentation expectations on Aetna. For pediatric IBD (infliximab biosimilars), pediatric rheumatology (adalimumab / etanercept biosimilars), and pediatric hematology / oncology (rituximab / bevacizumab biosimilars), Aetna’s pediatric criteria generally still require biosimilar step-through but provide more accommodation for continuing-patient stability arguments where switching could risk loss of response. Document the pediatric clinical course (date of diagnosis, prior therapies with dates and durations, current weight-based dosing) and any pediatric specialist opinion supporting non-switching.

Biosimilar exception criteria

Aetna will consider an exception to the biosimilar mandate when the prescriber documents one of: a prior trial of the preferred biosimilar with documented intolerance or AE; documented immunogenicity (anti-drug antibody formation) on the biosimilar; loss of clinical response on the biosimilar after switch; or a clinical situation where switching from reference to biosimilar carries documented risk (rare immunogenicity concerns in stable maintenance patients with specific clinical histories). The exception submission should include the prior therapy timeline, the AE or immunogenicity documentation, and the prescriber’s clinical rationale. The Cordavis adalimumab arrangement has its own exception language documented in Aetna’s 2024+ specialty drug Clinical Policy Bulletins.

Specialty pharmacy network

Aetna’s in-network specialty pharmacy ecosystem is anchored by CVS Specialty, the captive specialty pharmacy under the CVS Health umbrella (sibling to CVS Caremark and Cordavis). For most pharmacy-benefit specialty drugs, CVS Specialty is the default and frequently the only in-network specialty pharmacy under the member’s plan. A limited set of additional specialty pharmacies remain in-network for specific drug classes or specific manufacturer-mandated dispensing arrangements (e.g., REMS-restricted distribution).

White-bagging vs brown-bagging vs buy-and-bill

White-bagging (the specialty pharmacy dispenses the drug and ships it directly to the site of care, where it is administered) is Aetna’s preferred fulfillment model for designated specialty drugs and is mandatory for drugs on the Aetna / CVS Caremark white-bag specialty drug mandate list. The dispensing fee, drug cost, and shipping route through the pharmacy benefit (CVS Caremark + CVS Specialty), not through the practice’s buy-and-bill billing.

Brown-bagging (the specialty pharmacy ships the drug to the patient, who brings it to the site of care) is generally not permitted by Aetna for parenteral specialty drugs due to chain-of-custody and stability concerns.

Buy-and-bill (the practice purchases the drug, administers it, and bills the medical benefit for both the drug and the administration) remains the default for most chemotherapy and many oncology biologics administered in HOPD or community oncology settings, and for specialty drugs not on the Aetna white-bag mandate. Verify the current sourcing requirement for each drug before ordering inventory — a buy-and-bill claim for a drug on the CVS Specialty mandate list will be denied as out-of-network specialty pharmacy.

Step therapy requirements

Aetna enforces step therapy across the major specialty therapeutic areas. The most-mandated step-throughs in 2026 closely track UHC’s patterns with two notable Aetna-specific twists: the Cordavis adalimumab biosimilar mandate is the structural first-line for most plaque psoriasis / PsA / RA / IBD anti-TNF starts, and Aetna sometimes requires more frequent labs / imaging documentation on reauth than UHC.

Step therapy exception language

Aetna will consider a step therapy exception when the prescriber documents one of: intolerance (with specific AE description and date), contraindication (with ICD-10 code or clinical reason), failure (with specific clinical metric and treatment duration), or prior payer step-through grandfathering (the patient previously completed the step-through under a prior payer and continued response on the requested agent). Exception submissions should include the prior therapy timeline with dates, doses, durations, and documented outcome, plus the prescribing physician’s clinical rationale referenced to the cited Aetna Clinical Policy Bulletin.

Common denials and how to fix them

Appeals process

Aetna’s appeals structure has three levels for commercial pre-service appeals: Level 1 internal appeal (filed in writing within the timeframe stated in the denial letter, typically 180 days for commercial; TAT 30 days for pre-service); Level 2 internal appeal (filed if Level 1 upholds; TAT 30 days for pre-service); and external review by an Independent Review Organization (IRO) (filed if Level 2 upholds; TAT typically 45 days standard, 72 hours expedited). For Aetna Medicare Advantage and SilverScript Part D, the structure follows CMS rules: Plan Reconsideration → Independent Review Entity (IRE, Maximus or C2C) → ALJ → Medicare Appeals Council → Federal Court, with CMS-mandated TATs at each level. Always read the denial letter carefully for the deadline to file each level — missing the window forfeits the appeal right.

Reauthorization intervals

Reauth workflow

Calendar the reauth date 45-60 days before expiration. Refresh the clinical packet with: the most recent clinical note (within 30-60 days), current labs or imaging required by the drug class (Aetna sometimes asks for tighter labs currency than UHC — budget for an extra lab draw if the last set is older than 90 days for biologics with hepatic / hematologic monitoring expectations), current dose record showing on-label compliance, and any new diagnosis information. Submit the reauth through the same portal used for the original PA. If the reauth packet is submitted late and approval lapses, document any therapy continuation gap and prepare a justification for therapy continuation pending re-approval. Aetna’s grace policy for in-progress reauth varies by line of business and is not guaranteed.

Frequently asked questions

Which Aetna portal do I use to submit a specialty drug prior authorization?

It depends on the benefit channel and the dispensing model. For medical-benefit buy-and-bill drugs administered at an HOPD, infusion center, or office, submit through Availity Essentials (Aetna’s primary multi-payer provider portal) or the Aetna provider portal at aetna.com. For pharmacy-benefit specialty drugs administered by the PBM, submit through the CVS Caremark prior authorization portal at caremark.com or via CoverMyMeds. For drugs dispensed by CVS Specialty under a white-bag arrangement, the referral and PA flow through the CVS Specialty Pharmacy provider portal, often coordinated through the Naviport hub workflow tool. Picking the wrong portal stalls Aetna specialty PAs more than any other operational error.

What is the difference between Availity and the Aetna provider portal?

Availity Essentials is a multi-payer provider portal that includes Aetna along with most major commercial payers. Many practices submit to Aetna via Availity because the same login covers their other payers and the eligibility, claim status, and PA submission tools are unified. The Aetna provider portal at aetna.com is Aetna’s first-party provider site, which surfaces some Aetna-specific tools (PA forms by drug, Clinical Policy Bulletins, and certain Aetna-only programs). Both portals route the PA submission to the same Aetna review queue, but the Aetna provider portal sometimes carries the newest drug-specific PA form before Availity is updated. For routine submissions, Availity is faster operationally. For new drugs or recently revised PA criteria, check aetna.com for the current form.

Does Aetna require biosimilar step-through for Avastin, Herceptin, Remicade, Rituxan, and adalimumab?

Yes. Aetna has an aggressive biosimilar substitution policy across the major reference biologics. For new starts (and for continuing patients without documented clinical reason to stay on reference), Aetna requires a preferred biosimilar before the reference product for bevacizumab (Mvasi Q5107, Zirabev Q5118, Alymsys Q5126, Vegzelma Q5129), trastuzumab (Ogivri Q5114, Herzuma Q5113, Ontruzant Q5112, Trazimera Q5116, Kanjinti Q5117), infliximab (Inflectra Q5103, Renflexis Q5104, Avsola Q5121), rituximab (Truxima Q5115, Ruxience Q5119, Riabni Q5123), and pegfilgrastim biosimilars over Neulasta. For adalimumab, Aetna’s mandate leverages Cordavis (the CVS Health private-label subsidiary), which distributes select adalimumab biosimilars under an exclusive arrangement. Aetna’s adalimumab biosimilar mandate is operationally aggressive but tracks slightly behind UnitedHealthcare on continuing-patient mandatory switches.

What is Cordavis and how does it affect Aetna PA decisions?

Cordavis is a wholly-owned subsidiary of CVS Health launched in 2023 to co-produce and distribute private-label biosimilars, beginning with adalimumab. As Aetna is also a CVS Health subsidiary, the Cordavis-distributed adalimumab biosimilars (including Cordavis-branded Hyrimoz and Hadlima HD via partnership arrangements) are the preferred adalimumab biosimilars on Aetna formularies and on CVS Caremark’s specialty drug list. PA submissions for reference Humira on Aetna commercial plans typically require documented step-through on a Cordavis-distributed biosimilar (or an exception based on intolerance / immunogenicity / loss of response). The Cordavis arrangement is the structural reason Aetna’s adalimumab biosimilar mandate is enforced operationally through the CVS Caremark / CVS Specialty pipeline.

Does Aetna require white-bagging through CVS Specialty?

For most pharmacy-benefit specialty drugs, yes — CVS Specialty is the default in-network specialty pharmacy under Aetna commercial plans, and many self-administered injectables and increasingly office-administered biologics are dispensed white-bag from CVS Specialty to the site of care. Buy-and-bill remains the default for chemotherapy and many oncology biologics administered in HOPD or community oncology settings under the medical benefit, and for specialty drugs not on the Aetna / CVS Caremark white-bag mandate list. For drugs on the mandate list, sourcing through a non-CVS Specialty in-network specialty pharmacy can result in claim denial; always verify the current sourcing requirement for the specific drug and plan before ordering inventory.

What is the difference between SilverScript and Aetna Medicare Advantage for Part D and Part B drug coverage?

SilverScript is Aetna’s standalone Medicare Part D prescription drug plan (PDP) brand. It covers Part D drugs only and does not include Part B medical-benefit drug coverage. Aetna Medicare Advantage (Aetna MA) plans, including MA-PD plans, bundle Part A, Part B, and (for MA-PD) Part D coverage together. Part B drugs (most physician-administered drugs in the office or HOPD) under an Aetna MA plan are covered by the MA plan’s medical benefit and follow CMS Part B coverage rules plus Aetna MA’s additional medical-necessity criteria. Part D drugs (self-administered prescription drugs) under an Aetna MA-PD or under standalone SilverScript follow CMS Part D rules plus Aetna or SilverScript formulary tiers. The most common source of PA confusion at the practice is treating a Part B drug request as a Part D drug request (or vice versa) under an MA-PD member — verify the benefit channel before submitting.

How do I request an Aetna site-of-care exception for HOPD administration?

Submit the Aetna site-of-care exception language documented in the relevant Clinical Policy Bulletin alongside the drug PA through Availity Essentials or aetna.com. Document the specific clinical reason HOPD is necessary (prior Grade 3+ infusion reaction with intervention, hemodynamic instability, concurrent comorbidity requiring HOPD-level monitoring, complex pediatric or geriatric situation), the failed or contraindicated alternative sites (office-based infusion, ambulatory infusion suite, home infusion via Coram), the prescribing physician’s attestation, and the planned administration protocol. Aetna’s site-of-care decisions are typically made within the same TAT as the drug PA and are generally more flexible than UHC’s on first-cycle HOPD and pediatric / geriatric cases.

How do Aetna Better Health (Medicaid) and Aetna Medicare Advantage PA criteria differ from commercial?

Each line of business maintains a separate medical and pharmacy policy set. Aetna Better Health (the Medicaid managed-care book in participating states) follows state-specific Medicaid formulary and PA criteria layered on top of Aetna’s base Clinical Policy Bulletins, with state-by-state variation in step therapy and prior authorization. Aetna Medicare Advantage follows CMS Part B and Part D coverage rules with Aetna’s additional medical-necessity criteria for non-formulary requests and step edits. SilverScript follows CMS Part D rules with SilverScript formulary tiers. PA forms and submission portals are similar to commercial (Availity / aetna.com / CVS Caremark), but always confirm the criteria set against the member’s specific plan ID before submission — the same drug can have very different PA criteria across Aetna’s commercial, MA, SilverScript, and Better Health books.

Sources

• Availity Essentials — Aetna provider portal documentation, current calendar year. Accessible at availity.com (provider login required for PA tools). Paraphrased.
• Aetna provider portal — PA forms, Clinical Policy Bulletins, formulary documents. Accessible at aetna.com/providers.
• Aetna Clinical Policy Bulletins (CPBs) — medical-necessity criteria for specialty drugs, biosimilar substitution, site-of-care, and white-bagging mandate. Published on aetna.com.
• CVS Caremark provider portal — specialty PA criteria, formulary, and CVS Caremark Specialty Drug List, current calendar year. Accessible at caremark.com.
• CVS Specialty Pharmacy provider portal — specialty Rx referral, Naviport hub workflow documentation. Accessible at cvsspecialty.com/hcp.
• Cordavis (CVS Health subsidiary) public statements on adalimumab biosimilar private-label production and distribution arrangements with Aetna and other CVS Health-associated payers, 2023-2025.
• SilverScript — CMS Part D formulary and PA documentation for standalone SilverScript Part D PDP plans.
• CMS Part B and Part D coverage documents for Aetna Medicare Advantage and MA-PD plans, current calendar year.
• Aetna Better Health state-specific Medicaid managed care formularies; state Medicaid PA criteria for participating states.
• Coram (CVS Health home infusion) provider documentation for Aetna home-infusion coverage.
• AHIP specialty pharmacy guidance, current edition (cross-reference).
• BCBS Association biosimilar substitution policy framework (used as cross-reference for biosimilar mandate norms).

All sources are publicly available payer policy documents or paraphrased from trade-association educational materials. Payer policy URLs, fax numbers, and criteria change. Verify any operational detail (fax, portal URL, specific PA criteria) on aetna.com, Availity, or CVS Caremark’s provider portal before submission. The methodology by which we resolve source conflicts is described in the Methodology.

Related references